Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Guggenheim Upgrades Jade Biosciences to Buy, Announces $14 Price Target

Author: Benzinga Newsdesk | June 16, 2025 09:35am
Guggenheim analyst Vamil Divan upgrades Jade Biosciences (NASDAQ:JBIO) from Neutral to Buy and announces $14 price target.

Posted In: JBIO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist